UNSPSC 51412703: Naftidrofuryl hydrogen oxalate

This classification denotes a vasodilating agent and serotonin antagonist with the molecular formula C24H33NO3.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ADB8D9388, chemically known as 2-furanpropionic acid, tetrahydro-.alpha.-(1-naphthylmethyl)-, 2-(diethylamino)ethyl esteroxalate (1:1) but more generally known as nafronyl oxalate, which bears US NIH Compound Identifier 4417. European Medicines Agency schedules Nafronyl oxalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20719.

Most nations, for tariff and trade purposes, schedule naftidrofuryl hydrogen oxalate under HS 29321900. SMILES: CCN(CC)CCOC(=O)C(CC1CCCC2C1CCCC2)CC3CCCO3.C(=O)(C(=O)O)O.

UNSPSC 51412703 Naftidrofuryl hydrogen oxalate, a Commodity code, classifies pharmaceutical active ingredients and finished medications procured by state and local health agencies, fire departments, and cooperative purchasing alliances. State and local governments buying under this code source advanced life support medications, generic pharmaceuticals, and over-the-counter products for emergency medical services, employee health plans, and institutional pharmacy programs. The issuing bodies span municipal fire departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing consortiums (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Work being solicited includes sealed bids for specific medication line items with firm pricing and expedited delivery windows, state-level requests for information to evaluate direct-to-manufacturer pharmacy contracting models, and cooperative purchasing RFPs establishing multi-vendor supply agreements for generic pharmaceuticals with authorized wholesalers. Vendors must comply with FDA requirements, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, comprehensive insurance and bonding, Safety Data Sheets compliant with OSHA standards, and accessibility documentation including WCAG 2.2 Level AA conformance and Section 508 compliance.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications with a response deadline of April 8, 2026 (estimated contract value $40,000, one-year term plus renewal options and unilateral 30-day extensions), requiring four medication line items with nine-month minimum expiration dating and 365-day defect warranties; the solicitation carries a 5 percent Small Local Business Enterprise (SLBE) bid discount not to exceed $10,000. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a preliminary market-intelligence phase preceding formal RFP solicitation. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026; the RFP weights price competitiveness at 75 percent and requires vendors to maintain relationships with at least two of three authorized wholesalers and pay a 3 percent administrative fee on all contract purchases.